hypoglycemia and glp-1 Frontiers Role of Glucagon-Like Peptide-1 (GLP-1)
Description
Alm disso, alguns agonistas do GLP-1 demonstraram reduzir eventos cardiovasculares adversos em pacientes com alto risco cardiovascular (DIAS et al., 2016
A smaller percentage of patients experience more severe diarrhoea that may necessitate dose reduction or treatment discontinuation, as documented in the medicines' Summary of Product Characteristics (SmPCs)
Nearly three years since its launch, Mounjaro is selling around $3 billion a month, while Zepbound is on track to surpass that amount in a few months time
Weidinger C, Hegazy AN, Siegmund B
